57th ASH Annual Meeting and Exposition (December 5-8, 2015): 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Epigenetic Approaches

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation Oral and Poster Abstracts
Oral

W109, Level 1 (Orange County Convention Center)

Moderators:

Charles Craddock, BM, FRCP, FRCPath, Queen Elizabeth Hospital and Martha Arellano, Winship Cancer Institute of Emory University

Disclosures:

Craddock: Celgene: Consultancy , Honoraria , Research Funding ; Pfizer: Speakers Bureau ; Sunesis: Honoraria ; Johnson and Johnson: Consultancy .

7:00 AM

457

Novel Leukemia Stem Cell-Targeted Therapy for Acute Myeloid Leukemia Based on Dual Inhibition of Ezh1/Ezh2

Shuhei Fujita, MD, BS^1,2^*, Daisuke Honma, Ph.D.³^*, Nobuaki Adachi, Ph.D.³^*, Kazushi Araki, D.V.M., Ph.D.³^*, Emi Takamatsu, PhD¹^*, Kazumasa Aoyama, PhD⁴^*, Atsushi Iwama, MD, PhD⁴ and Issay Kitabayashi, PhD¹

¹Division of Hematological Malignancy, National Cancer Center Research Institute, Tokyo, Japan
²Department of Hematology, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan
³Oncology Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
⁴Department of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan

7:15 AM

458

Comparison of Efficacy and Safety Results in 103 Treatment-Naīve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Hagop M. Kantarjian, MD¹, Gail J. Roboz, MD², Patricia L. Kropf, MD³, Karen W.L. Yee, MD⁴, Casey L. O'Connell, MD⁵, Raoul Tibes, MD, PhD⁶, Katherine J. Walsh, MD⁷, Nikolai A. Podeltsev, MD⁸^*, Elizabeth A. Griffiths, MD⁹, Elias Jabbour¹, Guillermo Garcia-Manero, MD¹, David A. Rizzieri, MD¹⁰, Wendy Stock, MD¹¹, Michael R. Savona, MD¹², Todd L. Rosenblat, MD, MS¹³^*, Jesus G. Berdeja, MD¹⁴, Laksmi Wilson¹⁵^*, James N. Lowder, MD¹⁵^*, Pietro Taverna, PhD¹⁵^*, Yong Hao, PhD¹⁵^*, Mohammad Azab, MD¹⁵ and Jean-Pierre Issa, MD¹⁶

¹The University of Texas MD Anderson Cancer Center, Houston, TX
²Weill Cornell/NY Presbyterian Medical Center, New York, NY
³Fox Chase Cancer Center, Philadelphia, PA
⁴Princess Margaret Cancer Center, Toronto, ON, Canada
⁵University of Southern California, Keck School of Medicine, Los Angeles, CA
⁶Mayo Clinic Arizona, Scottsdale, AZ
⁷The Ohio State University, Columbus, OH
⁸Yale University School of Medicine, New Haven, CT
⁹Roswell Park Cancer Institute, Buffalo, NY
¹⁰Duke University Medical Center, Raleigh, NC
¹¹The University of Chicago Medical Center, Chicago, IL
¹²Vanderbilt University Medical Center, Nashville, TN
¹³New York-Presbyterian/Columbia University Medical Center, New York, NY
¹⁴Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
¹⁵Astex Pharmaceuticals, Inc., Pleasanton, CA
¹⁶Fels Institute, Temple University, Philadelphia, PA

7:30 AM

459

Inhibition of the Histone Demethylase LSD1 Combined with Caloric Restriction or IGF1/Insulin Inhibition Leads to Durable Responses in a Preclinical Model of Acute Myeloid Leukemia

Luca Mazzarella, MD, PhD¹^*, Tiphanie Durfort¹^*, Rani Pallavi¹^*, Elena Mylonas¹^*, Paolo Falvo¹^*, Anna Giulia Sanarico²^*, Massimo Stendardo¹^*, Luciano Giaco'¹^*, Anna Russo¹^*, Lucilla Luzi¹^*, Massimiliano Mazza¹^*, Giulia De Conti¹^*, Paola Vianello³^*, Pier Luigi Rossi¹^*, Elena Ceccacci¹^*, Mohamed Elgendy¹^*, Marco Giorgio¹^*, Ciro Mercurio^3,4^*, Saverio Minucci^1,3^* and Pier Giuseppe Pelicci¹

¹Dept of Experimental Oncology, European Institute of Oncology, Milan, Italy
²Tor Vergata University, Rome, Italy
³Drug Discovery Program and Drug Development Program, European Institute of Oncology, Milan, Italy
⁴Genextra Group, DAC s.r.l., Milan, Italy

7:45 AM

460

The Small Molecule Img-98, a Potent and Selective Inhibitor of the Lysine Demethylase Lsd-1, Effectively Augments the Pro-Differentiation Effects of ATRA in a Pre-Clinical Model of AML

Ronan T. Swords, MD, PhD, FRCPI, FRCPath¹, Aymee Perez, PhD²^*, Ana Rodriguez²^*, Justin M. Watts, MD²^*, Fernando Vargas, MD²^*, Roy Elias²^*, Hugh Y. Rienhoff Jr., MD³ and Arthur Zelent, PhD²

¹Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Hospitals, Miami, FL
²Sylvester Comprehensive Cancer Center, University of Miami, Miami
³Imago Biosciences, San Francisco

8:00 AM

461

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Naval Daver, MD¹, Hagop M. Kantarjian, MD², Guillermo Garcia-Manero, MD³, Elias Jabbour², Naveen Pemmaraju, MD², Kenneth Vaughan³^*, Sherry Pierce, BSN, BA²^*, Marina Konopleva, MD, PhD⁴, Tapan Kadia, MD², Courtney DiNardo, MD², Gautam Borthakur, MD², Jorge E. Cortes, MD², Adam R Craig, MD, PhD⁵ and Farhad Ravandi, MD²

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, TX
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
⁴Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Sunesis Pharmaceuticals Inc., South San Francisco

8:15 AM

462

MBNL1 As a New Therapeutic Target in MLL-Fusion Gene Leukemia

Svetlana S Itskovich, PhD¹^*, Jason Clark¹^*, James C. Mulloy, PhD², Matthew D Disney³^* and Ashish R Kumar, MBBS, PhD¹

¹Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
²Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
³The Scripps Research Institute, Department of Chemistry, Jupiter, FL

See more of: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

616.O1.6 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Epigenetic Approaches